Development of algorithms based on serum markers and Fibroscan for detecting significant fibrosis and cirrhosis in chronic hepatitis B patients: Significant reduction in liver biopsy

2016 Hepatology Research In press;

AIM: To develop algorithms for detecting significant fibrosis and cirrhosis in chronic hepatitis B (CHB) patients with the aim of reducing liver biopsy needed. METHODS: For 307 CHB patients, the aspartate aminotransferase-to-platelet ratio index (APRI), the fibrosis index based on the four factors (FIB-4) and the result of a Fibroscan (FS) were obtained when a liver biopsy was performed. All patients were classified based on APRI or FIB-4 score and further assessed by FS results. Patients who remained unclassified after two steps of evaluation were considered to need liver biopsy. RESULTS: Algorithm implementation found that APRI + FS significantly lowered liver biopsy required for detection of significant fibrosis than individual APRI or FS screening (65.1% vs 75.9% or 78.5%, p = 0.003 or /= 50 years old than APRI + FS (22.6% vs 56.5%, p

Pubmed : 26970087